Bioavailability, Ischemic Cerebrovascular Disease, Safety Issues
Conditions
Keywords
Nimodipine, bioavailability, Safety, ischemic cerebrovascular disease
Brief summary
A Randomized, Open-label, Single Dose, Two Formulation, Two Period, Double Cross Over Bioavailability Comparison Study of two types of Nimodipine Injections in Healthy Volunteers.
Detailed description
The investigation product Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd.And Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation.The volunteers were administered with Nimodipine injection for intravenous infusion (containing nimodipine 11 mg) for 12 consecutive hours, respectively.The Venous blood was collected at 0 hours before the administration (ie, 1 hour before the administration) and 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h (Administration was over) and 12.5 h, 13 h, 14 h, 16 h, 19 h, 22 h, 25 h, 36 h, 3 ml per blood collection.
Interventions
DRUGNimodipine Injection
Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
DRUGNimodipine Injection (II)
Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
Sponsors
Xuanwu Hospital, Beijing
Shenyang Dongxing Pharmaceutical Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Sign the informed consent form before the study, and fully understand the test content, process and possible adverse reactions, and be able to comply with the protocol according to the test plan requirements; 2. Healthy subjects, both male and female; 3. Age ≥ 18 years old; 4. Male weight ≥ 50 kg, female weight ≥ 45 kg, body mass index in the range of 19 \ 26 (including the critical value)\[Body mass index (BMI) = weight (kg) / height 2 (m2)\].
Exclusion criteria
\- Subject who is in one of the following conditions may not be eligible. 1. Those who smoke more than 5 cigarettes per day for 3 months before the test or who cannot stop smoking during the trial period; 2. Allergies, such as those who are allergic to drugs, food and pollen, or those known to be allergic to nimodipine; 3. Those who have a history of alcohol abuse 6 months before the test (defined as drinking 14 units of alcohol per week: 1 unit = 285 ml of beer, or high-alcohol (50% or more alcohol) 25 ml, or 150 ml of wine) or Drinkers cannot be stopped during the trial; 4. Donor blood or a large amount of blood loss ≥400 ml (excluding female menstrual blood volume) within 3 months before the test, or have a history of halo and fainting; 5. Anyone taking any drug within 14 days before the test; 6. Antidepressants (such as fluoxetine), nortriptyline, norfloxacin, anti-HIV drugs (such as azidothymidine), calcium antagonists (such as nifedipine), were used within 28 days prior to the test. Diltiazem, verapamil, alpha-methyldopa and other antihypertensive drugs; 7. Have taken the study drug within 3 months before the test, or participated in any drug or medical device clinical trial; 8. Clinical laboratory examination, vital signs, physical examination, and 12-lead ECG abnormalities in the screening period are clinically significant; 9. During screening, when staying in the clinical center, the supine pressure of the supine position is not in the range of 100\ 139 mmHg, and the diastolic pressure in the supine position is not in the range of 60\ 89 mmHg; 10. During screening, when staying in the clinical center, the pulse is not in the range of 60\ 100 beats/min before each dose; 11. There is a serious arrhythmia: QTc interval prolongation (QTc over 450 ms), or QTc interval prolongation syndrome or family history of sudden death 12. A positive result of screening for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody or Treponema pallidum-specific antibody; 13. Health status: a history of major diseases or important organ diseases such as nervous system, mental system, respiratory system, cardiovascular system, digestive system, blood system, endocrine system, musculoskeletal or metabolic abnormalities; 14. pregnant and lactating women; 15. Female subjects of childbearing age have a pregnancy plan or unable to take effective contraception after the first dose and within 3 months after the last dose, from 30 days before screening to 3 months after the last dose. Measures (non-pharmaceutical contraception), see the appendix for specific contraceptive measures; 16. Can not stop taking chocolate, any caffeinated food or drink during the test; or eat any food or drink containing grapefruit ingredients 14 days before the first dose to the end of the test; 17. Those who are positive for alcohol screening before dosing, or who have taken any alcoholic products within 24 hours prior to dosing; 18. Those who are positive for drug screening, who have had a history of drug abuse in the past five years or who have used drugs three months before the trial; 19. Investigators believe that it is not appropriate to participate in this test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC | Within 36 hours after starting the administration | Evaluation of bioequivalence based on pharmacokinetic parameters such as AUC |
| Cmax | Within 36 hours after starting the administration | Evaluation of bioequivalence based on pharmacokinetic parameters such as Cmax |
Countries
China
Contacts
Primary ContactZhang Lan, Doctor
Outcome results
None listed